Gena Wang
Stock Analyst at Barclays
(2.33)
# 2,424
Out of 5,182 analysts
242
Total ratings
42.14%
Success rate
-1.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $87 → $95 | $66.05 | +43.83% | 7 | Apr 6, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $90 → $80 | $26.50 | +201.89% | 8 | Feb 4, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $24.81 | +101.53% | 7 | Nov 24, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $9.44 | +249.58% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $47.30 | -47.15% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $13.87 | +0.94% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.18 | +463.06% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $65.49 | +3.83% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $22.04 | -9.26% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $429.85 | -3.69% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $7.23 | +24.48% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $9.20 | -2.17% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $297.93 | +76.89% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $75.45 | +25.91% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $55.46 | +44.25% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $3.71 | +115.63% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $42.26 | -59.77% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $9.39 | +294.04% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $12.87 | +381.74% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $53.58 | +4.52% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $30.08 | -30.19% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $10.18 | +204.52% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $3.00 | - | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $26.78 | -66.39% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $8.57 | +191.72% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $9.70 | +85.57% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $7.53 | +19.52% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.95 | +4,521.85% | 1 | Jan 6, 2017 |
Cytokinetics
Apr 6, 2026
Maintains: Overweight
Price Target: $87 → $95
Current: $66.05
Upside: +43.83%
Legend Biotech
Feb 4, 2026
Maintains: Overweight
Price Target: $90 → $80
Current: $26.50
Upside: +201.89%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $24.81
Upside: +101.53%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $9.44
Upside: +249.58%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $47.30
Upside: -47.15%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $13.87
Upside: +0.94%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.18
Upside: +463.06%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $65.49
Upside: +3.83%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $22.04
Upside: -9.26%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $429.85
Upside: -3.69%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $7.23
Upside: +24.48%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $9.20
Upside: -2.17%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $297.93
Upside: +76.89%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $75.45
Upside: +25.91%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $55.46
Upside: +44.25%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.71
Upside: +115.63%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $42.26
Upside: -59.77%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $9.39
Upside: +294.04%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $12.87
Upside: +381.74%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $53.58
Upside: +4.52%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $30.08
Upside: -30.19%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $10.18
Upside: +204.52%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $3.00
Upside: -
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $26.78
Upside: -66.39%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $8.57
Upside: +191.72%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $9.70
Upside: +85.57%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $7.53
Upside: +19.52%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.95
Upside: +4,521.85%